News Sobi stays on its acquisitive streak with $915m Dova deal Sweden’s Sobi has added another already-marketed product to its rare disease portfolio via a $29 per share takeover of Dova
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face